emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide · EMTRICITABINE 200 mg/1; RILPIVIRINE HYDROCHLORIDE 25 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 · Tablet · Oral · Gilead Sciences, Inc.
NDC 61958-2101-01 · 30 TABLET in 1 BOTTLE, PLASTIC · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $130.29 per unit over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
price up 5% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| patent | 8754065*PED | Feb 15, 2033 |
| patent | 9296769*PED | Feb 15, 2033 |
| patent | 9296769 | Aug 15, 2032 |
| patent | 8754065 | Aug 15, 2032 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Gilead Sciences, Inc. | EMTRICITABINE 200 mg/1; RILPIVIRINE HYDROCHLORIDE 25 mg/1; TENOFOVIR ALAFENAMIDE FUMARATE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Odefsey — NDC 61958-2101-01," retrieved September 3, 2026, https://drugdashboards.com/drug/61958210101.
Free to cite with attribution — see how the data is put together.